228 related articles for article (PubMed ID: 7805177)
1. In vivo screening models of cisplatin-resistant human lung cancer cell lines using SCID mice.
Heike Y; Takahashi M; Ohira T; Arioka H; Funayama Y; Nishio K; Ogasawara H; Saijo N
Cancer Chemother Pharmacol; 1995; 35(3):200-4. PubMed ID: 7805177
[TBL] [Abstract][Full Text] [Related]
2. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).
Ohmori T; Morikage T; Sugimoto Y; Fujiwara Y; Kasahara K; Nishio K; Ohta S; Sasaki Y; Takahashi T; Saijo N
Jpn J Cancer Res; 1993 Jan; 84(1):83-92. PubMed ID: 8383649
[TBL] [Abstract][Full Text] [Related]
3. The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo.
Nishi M; Abe Y; Fujimori S; Hamamoto A; Inoue Y; Miyazaki N; Oida Y; Ikoma N; Ohnishi Y; Yamazaki H; Ueyama Y; Nakamura M
Oncol Rep; 2005 Aug; 14(2):421-4. PubMed ID: 16012725
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
Fukuda M; Ohe Y; Kanzawa F; Oka M; Hara K; Saijo N
Anticancer Res; 1995; 15(2):393-8. PubMed ID: 7763011
[TBL] [Abstract][Full Text] [Related]
5. In vitro cytotoxicity of a novel antitumor antibiotic, spicamycin derivative, in human lung cancer cell lines.
Lee YS; Nishio K; Ogasawara H; Funayama Y; Ohira T; Saijo N
Cancer Res; 1995 Mar; 55(5):1075-9. PubMed ID: 7866991
[TBL] [Abstract][Full Text] [Related]
6. Non-cross resistance of ZD0473 in acquired cisplatin-resistant lung cancer cell lines.
Kawamura-Akiyama Y; Kusaba H; Kanzawa F; Tamura T; Saijo N; Nishio K
Lung Cancer; 2002 Oct; 38(1):43-50. PubMed ID: 12367792
[TBL] [Abstract][Full Text] [Related]
7. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts.
Nemati F; Livartowski A; De Cremoux P; Bourgeois Y; Arvelo F; Pouillart P; Poupon MF
Clin Cancer Res; 2000 May; 6(5):2075-86. PubMed ID: 10815935
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin.
Twentyman PR; Wright KA; Mistry P; Kelland LR; Murrer BA
Cancer Res; 1992 Oct; 52(20):5674-80. PubMed ID: 1327513
[TBL] [Abstract][Full Text] [Related]
9. Radiation sensitivities in various anticancer-drug-resistant human lung cancer cell lines and mechanism of radiation cross-resistance in a cisplatin-resistant cell line.
Oshita F; Fujiwara Y; Saijo N
J Cancer Res Clin Oncol; 1992; 119(1):28-34. PubMed ID: 1400562
[TBL] [Abstract][Full Text] [Related]
10. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
[TBL] [Abstract][Full Text] [Related]
11. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin.
Kasahara K; Fujiwara Y; Nishio K; Ohmori T; Sugimoto Y; Komiya K; Matsuda T; Saijo N
Cancer Res; 1991 Jun; 51(12):3237-42. PubMed ID: 1645616
[TBL] [Abstract][Full Text] [Related]
12. The subunits of glutamate cysteine ligase enhance cisplatin resistance in human non-small cell lung cancer xenografts in vivo.
Fujimori S; Abe Y; Nishi M; Hamamoto A; Inoue Y; Ohnishi Y; Nishime C; Matsumoto H; Yamazaki H; Kijima H; Ueyama Y; Inoue H; Nakamura M
Int J Oncol; 2004 Aug; 25(2):413-8. PubMed ID: 15254739
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic correlation between experimental and clinical effects on human non-small cell lung cancers of cis-diammineglycolatoplatinum (254-S) and cis-diamminedichloroplatinum.
Koenuma M; Kasai H; Uchida N; Wada T; Hattori M; Oguma T; Totani T; Inaba M
Anticancer Res; 1995; 15(2):417-21. PubMed ID: 7763015
[TBL] [Abstract][Full Text] [Related]
14. Alteration of type II regulatory subunit of cAMP-dependent protein kinase in human cisplatin-resistant cells as a basis of collateral sensitivity to 8-chloro-cAMP.
Nishio K; Morikage T; Kubota N; Ohmori T; Takeda Y; Fujiwara Y; Miki K; Abe K; Saijo N
Jpn J Cancer Res; 1992 Jul; 83(7):754-60. PubMed ID: 1325432
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells.
Basu A; Weixel K; Saijo N
Cell Growth Differ; 1996 Nov; 7(11):1507-12. PubMed ID: 8930400
[TBL] [Abstract][Full Text] [Related]
16. Establishment and characterization of cisplatin-resistant sublines of human lung cancer cell lines.
Hong WS; Saijo N; Sasaki Y; Minato K; Nakano H; Nakagawa K; Fujiwara Y; Nomura K; Twentyman PR
Int J Cancer; 1988 Mar; 41(3):462-7. PubMed ID: 3346112
[TBL] [Abstract][Full Text] [Related]
17. Chemosensitivity and radiosensitivity of small cell lung cancer cell lines studied by a newly developed 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) hybrid assay.
Hida T; Ueda R; Takahashi T; Watanabe H; Kato T; Suyama M; Sugiura T; Ariyoshi Y; Takahashi T
Cancer Res; 1989 Sep; 49(17):4785-90. PubMed ID: 2547517
[TBL] [Abstract][Full Text] [Related]
18. Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo.
Jafri SH; Glass J; Shi R; Zhang S; Prince M; Kleiner-Hancock H
J Exp Clin Cancer Res; 2010 Jul; 29(1):87. PubMed ID: 20594324
[TBL] [Abstract][Full Text] [Related]
19. Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.
Sasaki Y; Shinkai T; Eguchi K; Tamura T; Ohe Y; Ohmori T; Saijo N
Cancer Chemother Pharmacol; 1991; 27(4):263-70. PubMed ID: 1847845
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.
Kim DK; Kim HT; Cho YB; Tai JH; Ahn JS; Kim TS; Kim KH; Hong WS
Cancer Chemother Pharmacol; 1995; 35(5):441-5. PubMed ID: 7850928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
